康艾注射液联合培美曲塞与顺铂方案治疗肺腺癌的临床研究

A clinical study of Kang Ai injection combined with pemetrexed and cisplatin in the treatment of lung adenocarcinoma

目的探讨康艾注射液联合培美曲塞+顺铂方案治疗肺腺癌的疗效及不良反应。方法选取100例肺腺癌患者,采用随机数字表法将患者分为治疗组(康艾注射液+培美曲塞+顺铂)和对照组(培美曲塞+顺铂),每组各50例。比较两组患者的疗效、不良反应及生存情况。结果治疗组和对照组患者的客观有效率均为50%,两组比较无差异。治疗组患者1~3级白细胞和血小板下降及恶心呕吐的发生率分别为34%、12%、76%,对照组分别为62%、36%、86%,差异均有统计学意义(P﹤0.05)。治疗组患者血红蛋白减少及转氨酶升高的发生率与对照组比较,差异均无统计学意义(P﹥0.05)。治疗组和对照组患者的1年生存率分别为60.4%、56.6%,2年生存率分别为27.4%、29.0%,两组比较差异均无统计学意义(P﹥0.05)。结论康艾注射液联合培美曲塞+顺铂方案治疗肺腺癌可在一定程度上改善患者的生存质量,减轻化疗不良反应,值得临床应用研究。

Objective To investigate the clinical efficacy and adverse reactions of Kang Ai injection combined with pemetrexed and cisplatin in the treatment of lung adenocarcinoma. Method 100 patients with lung adenocarcinoma were enrolled and divided into treatment group （Kang Ai injection＋pemetrexed＋cisplatin） and control group （peme-trexed＋cisplatin） by a random table, with 50 cases in each group. The clinical efficacy, adverse reactions and survival rates were compared between two groups. Result The objective response rate of both groups was 50%, and there was no significant difference. The incidences of grade 1 to 3 leucopenia and thrombocytopenia, nausea and vomiting were 34%, 12%and 76%in treatment group,and 62%, 36%and 86%in control group, all the differences were statistically signifi-cant （P〈0.05）. The incidences of decreased hemoglobin and elevated transaminase level were similar in treatment group and control group, and the differences were not statistically significant （P〉0.05）. The 1-year survival rate in treatment group and control group was 60.4%and 56.6%, respectively, and the 2-year survival rate was 27.4%and 29.0%, respec-tively, the differences were not statistically significant （P〉0.05）. Conclusion The combination therapy of Kang Ai injec-tion, pemetrexed and cisplatin can improve the quality of life of patients with lung adenocarcinoma, and reduce adverse reactions. It is worthy of clinical application.